Search

Your search keyword '"Ludwig, W"' showing total 43 results
Start Over Author "Ludwig, W" Topic acute myeloid leukemia
43 results on '"Ludwig, W"'

1. Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach

Author

the German AML Cooperative Group, Büchner, T., Hiddemann, W., Berdel, W. E., Wörmann, B., Schoch, C., Löffler, H., Haferlach, T., Staib, P., Grüneisen, A., Aul, C., Giagounidis, A., Heyll, A., Lengfelder, E., Ludwig, W. -D., Maschmeyer, G., Rasche, H., Eimermacher, H., Balleisen, L., Pielken, H. J., Reis, H. E., Griesinger, F., Reichle, A., Schott, G., Sauerland, M. C., Heinecke, A., Hiddemann, Wolfgang, editor, Haferlach, Torsten, editor, Unterhalt, Michael, editor, Büchner, Thomas, editor, and Ritter, Jörg, editor

Published
2003
Full Text
View/download PDF

4. Mobilization of Peripheral Blood Stem Cells after Intensive Induction and Consolidation Therapy in Adult Patients with De Novo AML

Author

Wörmann, B., Heyll, A., Aswald, J., Aswald, S., Staib, P., Notter, M., Lengfelder, E., Meidenbauer, N., Reichle, A., Matylis, A., Ludwig, W. D., Hiddemann, W., Büchner, Th., Berdel, W. E., editor, Büchner, Th., editor, Kienast, J., editor, Van De Loo, J., editor, Jürgens, H., editor, Ritter, J., editor, and Vormoor, J., editor

Published
2000
Full Text
View/download PDF

5. Hematopoietic Growth Factors: Supportive and Priming Effects in AML

Author

A. Heinecke for the AMLCG, Büchner, T., Hiddemann, W., Zühlsdorf, M., Wörmann, B., Aswald, J., Aswald, S., Maschmeyer, G., Ludwig, W.-D., Sauerland, M.-C., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

6. Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia

Author

Schott, G., Grüneisen, A., Fülle, H. H., Sperling, C., Notter, M., Kerschgens, C., Krahl, D., Blau, W., Pasold, R., Neubauer, A., Klinkenstein, C., Schwartz, S., Arnold, R., Hellriegel, K.-P., Huhn, D., Thiel, E., Dörken, B., Ludwig, W.-D., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

7. Superiority of High-Dose over Intermediate-Dose Cytosine Arabinoside (AraC) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia (AML)

Author

Kern, W., Aul, C., Maschmeyer, G., Schönrock-Nabulsi, R., Ludwig, W. D., Bartholomäus, A., Bettelheim, P., Wörmann, B., Büchner, Th., Hiddemann, W., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

8. Biologic Determinants for AML Therapy

Author

German AML Cooperative Group, Haferlach, T., Löffler, H., Gassmann, W., Fonatsch, C., Schoch, C., Haase, D., Schlegelberger, B., Ludwig, W.-D., Thiel, E., Heinecke, A., Sauerland, M. C., Wörmann, B., Hiddemann, W., Büchner, Th., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

10. Growth Factors in AML: Updates

Author

Büchner, T., Hiddemann, W., Wörmann, B., Zühlsdorf, M., Rottmann, R., Innig, G., Maschmeier, G., Ludwig, W.-D., Sauerland, M.-C., Heinecke, A., Büchner, T., editor, Schellong, G., editor, Ritter, J., editor, Creutzig, U., editor, Hiddemann, W., editor, and Wörmann, B., editor

Published
1997
Full Text
View/download PDF

11. Cytomorphology and Clinical Outcome in 80 Patients with AML M4Eo and Inversion 16

Author

Haferlach, T., Löffler, H., Bennett, J. M., Andersen, J. W., Gassmann, W., Schoch, R., Paietta, E., Cassileth, P. A., Fonatsch, C., Schoch, C., Schlegelberger, B., Becher, R., Thiel, E., Ludwig, W.-D., Sauerland, M. C., Heinecke, A., Büchner, T., Büchner, T., editor, Schellong, G., editor, Ritter, J., editor, Creutzig, U., editor, Hiddemann, W., editor, and Wörmann, B., editor

Published
1997
Full Text
View/download PDF

16. Hematologic and Therapeutic Effects of High-Dose AraC/Mitoxantrone (HAM) in the Induction Treatment of Patients with Newly Diagnosed AML. A Trial by AML Cooperative Group

Author

Büchner, T., Hiddemann, W., Wörmann, B., Boeckmann, A., Löffler, H., Gaßmann, W., Maschmeyer, G., Ludwig, W.-D., Lengfelder, E., Heyll, A., Lathan, B., Innig, G., Freire-Innig, E. Augion, Buntkirchen, K., Sauerland, M. C., Heinecke, A., Hiddemann, W., editor, Plunkett, W., editor, Büchner, T., editor, Ritter, J., editor, Wörmann, B., editor, Keating, M. J., editor, and Creutzig, U., editor

Published
1996
Full Text
View/download PDF

18. Acute Myeloid Leukemia with Translocation (8;21). Cytomorphology, Dysplasia and Prognostic Factors in 41 Cases

Author

AML Cooperative Group and ECOG, Haferlach, T., Bennett, J. M., Löffler, H., Gassmann, W., Andersen, J., Tuzuner, N., Cassileth, P. A., Fonatsch, C., Schlegelberger, B., Thiel, E., Ludwig, W.-D., Sauerland, M. C., Heinecke, A., Büchner, Th., Hiddemann, W., editor, Plunkett, W., editor, Büchner, T., editor, Ritter, J., editor, Wörmann, B., editor, Keating, M. J., editor, and Creutzig, U., editor

Published
1996
Full Text
View/download PDF

20. Chemotherapy Intensity and Long-Term Outcome in AML

Author

AML Cooperative Group, Büchner, T., Hiddemann, W., Wörmann, B., Maschmeyer, G., Heit, W., Aul, C., Heyll, A., Löffler, H., Gassmann, H., Fülle, H. H., Hellriegel, K. P., Ludwig, W.-D., Lengfelder, E., Lathan, B., Emmerich, B., Schaefer, U. W., Sauerland, M. C., Heinecke, A., Büchner, T., editor, Hiddemann, W., editor, Wörmann, B., editor, Schellong, G., editor, and Ritter, J., editor

Published
1994
Full Text
View/download PDF

21. Immunophenotype of Acute Myeloid Leukemia: Correlation with Morphological Characteristics and Therapy Response

Author

Sperling, C., Seibt-Jung, H., Gassmann, W., Komischke, B., Sauerland, C., Hiddemann, W., Löffler, H., Büchner, T., Thiel, E., Ludwig, W.-D., Herfarth, Ch., editor, Senn, H.-J., editor, Baum, M., editor, Diehl, V., editor, Gutzwiller, F., editor, Rajewsky, M. F., editor, Wannenmacher, M., editor, Ludwig, Wolf-Dieter, editor, and Thiel, Eckhard, editor

Published
1993
Full Text
View/download PDF

22. Susceptibility of Human Leukemia Cells to Allogeneic and Autologous Lymphokine-Activated Killer Cells and Its Augmentation by Exposure of Leukemia Target Cells to Cytotoxic Drugs In Vitro and In Vivo

Author

Teichmann, J. V., Ludwig, W.-D., Thiel, E., Herfarth, Ch., editor, Senn, H.-J., editor, Baum, M., editor, Diehl, V., editor, Gutzwiller, F., editor, Rajewsky, M. F., editor, Wannenmacher, M., editor, Ludwig, Wolf-Dieter, editor, and Thiel, Eckhard, editor

Published
1993
Full Text
View/download PDF

24. Chemotherapy for Adult Acute Myeloid Leukemia: Study Results from the Acute Myeloid Leukemia Cooperative Group and Overview

Author

Büchner, T., Hiddemann, W., Löffler, H., Urbanitz, D., Koch, P., Maschmeyer, G., Wendt, F., Kuse, R., Mohr, A., Ludwig, W. D., Thiel, E., Seibt, H., Gassmann, W., Aul, C., Fuhr, H., Mertelsmann, R., Anders, C. H., Nowrousian, M. R., Straif, K., Vaupel, K. A., Hossfeld, D., von Paleske, A., Ho, A., Fülle, H. H., Hellriegel, K.-P., König, H. J., Emmerich, B., Lengfelder, E., Siegert, W., Bartels, H., Schwammborn, J., Bonhuijsen-Ant, R., Overkamp, F., Planker, M., Middelhoff, G., Mainzer, K., Zurborn, K. H., Köppler, H., Nowicki, L., Augener, W., Karow, J., Schroeder, M., Eimermacher, H., Heinecke, A., Sauerland, M. C., and Fleischer, J., editor

Published
1993
Full Text
View/download PDF

25. High-Dose Versus Intermediate-Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age-Adjusted Randomized Comparison

Author

Hiddemann, W., Aul, C., Maschmeyer, G., Schönrock-Nabulsi, R., Ludwig, W. D., Bartholomäus, A., Bettelheim, P., Becker, K., Balleisen, L., Lathan, B., Köppler, H., Grüneisen, T., Donhuijsen-Ant, R., Reichle, A., Heinecke, A., Sauerland, C., Büchner, T., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Plunkett, W., editor, Keating, M., editor, and Andreeff, M., editor

Published
1992
Full Text
View/download PDF

26. Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Following Chemotherapy in Patients with High-Risk AML

Author

Büchner, T., Hiddemann, W., Koenigsmann, M., Zühlsdorf, M., Wörmann, B., Boeckmann, A., Freire, E. Aguion, Innig, G., Maschmeyer, G., Ludwig, W.-D., Sauerland, M.-C., Heinecke, A., Schulz, G., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Plunkett, W., editor, Keating, M., editor, and Andreeff, M., editor

Published
1992
Full Text
View/download PDF

31. Proposal for the Classification of Relapsed and Refractory Acute Myeloid Leukemias as the Basis for an Age-Adjusted Randomized Comparison of Sequentially Applied High-Dose Versus Intermediate-Dose Cytosine Arabinoside in Combination with Mitoxantrone (S-HAM)

Author

Hiddemann, W., Aul, H. C., Maschmeyer, G., Urbanitz, D., Lathan, B., Reichle, A., Köppler, H., Donhuijsen-Ant, R., Ludwig, W. D., Grüneisen, T., Bettelheim, P., Schroyens, W., Balleisen, L., Bartels, H., Sauerland, C., Heinecke, A., Büchner, T., Büchner, T., editor, Schellong, G., editor, Hiddemann, W., editor, and Ritter, J., editor

Published
1990
Full Text
View/download PDF

34. Intensified Therapy for AML:The Role of the HAM Combination

Author

Büchner, T., Hiddemann, W., Wörmann, B., Löffler, H., Haferlach, T., Gassmann, W., Staib, P., Heyll, A., Aul, C., Lengfelder, E., Maschmeyer, G., Ludwig, W.-D., Fonatsch, C., Haase, D., Schoch, C., Sauerland, M.-C., Heinecke, A., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

35. Therapeutic and Prognostic Factors in the Management of Acute Myeloid Leukemia

Author

Büchner, T., Hiddemann, W., Wörmann, B., Löffler, H., Gassmann, W., Haferlach, T., Goasguen, J., Fonatsch, C., Becher, R., Hossfeld, D., Lengfelder, E., Ludwig, W.-D., Maschmeyer, G., Innig, G., Aul, H.-C., Heyll, A., Lathan, B., Staib, R., Hellriegel, K.-P., Fülle, H.-H., Heinecke, A., Sauerland, M. C., Büchner, T., editor, Schellong, G., editor, Ritter, J., editor, Creutzig, U., editor, Hiddemann, W., editor, and Wörmann, B., editor

Published
1997
Full Text
View/download PDF

36. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo

Author

Haferlach, T., Gassmann, W., Löffler, H., Jürgensen, C., Noak, J., Ludwig, W. -D., Thiel, E., Haase, D., Fonatsch, C., Becher, R., Schlegelberger, B., Nowrousian, M. R., Lengfelder, E., Eimermacher, H., Weh, H. J., Braumann, D., Maschmeyer, G., Koch, P., Heinecke, A., Sauerland, M. C., and T. Büchner for the AML Cooperative Group

Published
1993
Full Text
View/download PDF

40. Expression of cell-cell interacting genes distinguishes HLXB9/TEL from MLL-positive childhood acute myeloid leukemia.

Author

Wildenhain, S., Ruckert, C., Röttgers, S., Harbott, J., Ludwig, W.-D., Schuster, F. R., Beldjord, K., Binder, V., Slany, R., Hauer, J., Borkhardt, A., and Röttgers, S

Subjects
LETTERS to the editor, ACUTE myeloid leukemia in children, COMPARATIVE studies, DNA probes, KARYOTYPES, RESEARCH methodology, MEDICAL cooperation, NUCLEOTIDES, POLYMERASE chain reaction, PROTEINS, RESEARCH, TRANSCRIPTION factors, TRANSFERASES, EVALUATION research, ACUTE myeloid leukemia
Abstract

A letter to the editor is presented in context with expression of cell-cell interacting genes as the factor distinguishing HLXB9/TEL from MLL-positive childhood acute myeloid leukemia.

Published
2010
Full Text
View/download PDF

41. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.

Author

Béné, M.C., Castoldi, G., Knapp, W., Rigolin, G.M., Escribano, L., Lemez, P., Ludwig, W.-D., Matutes, E., Orfao, A., Lanza, F., and van't Veer, M.

Subjects
PLASMINOGEN activators, UROKINASE, ACUTE myeloid leukemia, GENE expression, PLASMA cells, MULTIPLE myeloma
Abstract

The analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma. The distribution of CD87 in acute myeloid leukemia (AML) varies according to the FAB subtype (highest expression in M5 and lowest in M0). Functionally, it is conceivable that the expression of CD87 could contribute to the invasive properties of the leukemic cells towards the skin and mucosal tissues as reflected by the clinical behavior of CD87 high cases. The lack of or weaker expression of CD87 on blast cells from ALL patients supports the concept that CD87 investigation might help in the distinction of AMLs from lymphoid malignancies. Among lymphoproliferative disorders, the expression of CD87 is exclusively found in pathological plasma cells. Since plasma cells also coexpress some adhesion molecules such as CD138 and CD56, this observation is consistent with the capacity of these cells to home in the bone compartment. High levels of soluble uPAR appear to represent an independent factor predicting worse prognosis and extramedullary involvement in multiple myeloma.Leukemia (2004) 18, 394-400. doi:10.1038/sj.leu.2403250 Published online 11 December 2003 [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

42. Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2.

Author

Hilgenfeld, E., Padilla-Nash, H., McNeil, N., Knutsen, T., Montagna, C., Tchinda, J., Horst, J., Ludwig, W.-D., Serve, H., Büchner, T., Berdel, W. E., Schröck, E., and Ried, T.

Subjects
KARYOTYPES, ACUTE myeloid leukemia, CHROMOSOME analysis
Abstract

Recurring chromosomal aberrations are of aetiological, diagnostic, prognostic and therapeutic importance in acute myeloid leukaemia (AML). However, aberrations are detected in only two thirds of AML cases at diagnosis and recurrent balanced translocations in only 50%. Spectral karyotyping (SKY) enables simultaneous visualization of all human chromosomes in different colours, facilitating the comprehensive evaluation of chromosomal abnormalities. Therefore, SKY was used to characterize 37 cases of newly diagnosed AML-M2, previously analysed using G-banding. In 15/23 patients it was possible to obtain metaphases from viably frozen cells; in 22 additional cases, fixed-cell suspensions were used. Of the 70 chromosomal aberrations identified by SKY, 30 aberrations were detected for the first time, 18 aberrations were redefined and 22 were confirmed. SKY detected two reciprocal translocations, t(X;3) and t(11;19). In five cases, eight structural aberrations resulted in partial gains of chromosome 21, six of which were undetected by G-banding. In 4/5 cases, these resulted in copy number increases for AML1. Amplification of MYC was detected in three cases. Using SKY and FISH, clonal aberrations were identified in 5/18 cases with a presumed normal karyotype; 3/5 aberrations were of known unfavourable prognostic significance. Karyotypes were entered into a custom-designed SKY database, which will be integrated with other cytogenetic and genomic databases. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

43. Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients.

Author

Bohlander, S.K., Muschinsky, V., Schrader, K., Siebert, R., Schlegelberger, B., Harder, L., Schemmel, V., Fonatsch, C., Ludwig, W.-D., Hiddemann, W., and Dreyling, M.H.

Subjects
ACUTE myeloid leukemia, CHROMOSOMAL translocation, AMINO acids, CHROMOSOME abnormalities, CHROMOSOMES, DNA, DNA probes, DOCUMENTATION, GENES, LYMPHOBLASTIC leukemia, LYMPHOMAS, NUCLEOTIDES, POLYMERASE chain reaction, PROTEINS, MYELOID leukemia, REVERSE transcriptase polymerase chain reaction
Abstract

The recurring translocation t(10;11)(p13;q14) which is found in acute myeloid leukemia (AML) and in acute lymphoblastic leukemia (ALL) results in the fusion of the putative transcription factor AF10 to CALM encoding a clathrin assembly protein. Previous studies using mainly fluorescence in situ hybridization (FISH) analysis have shown that the CALM/AF10 rearrangement is found in immature acute myeloid leukemia (AML) of subtype M0 and M1 and in T cell ALL. In this study we analyzed the CALM/AF10 and AF10/CALM fusion mRNAs in a series of three patients with AML, one patient with T-ALL and two patients with precusor T lymphoblastic lymphoma. In all six patients the breakpoint in CALM is at the 3' end of the coding region (nt1926/1927 or nt 2091/2092). Three breakpoints could be identified in AF10 (nt 588/589, nt 882/883 and nt 978/979). These data demonstrate that the CALM/AF10 fusions found in patients differ only slightly with respect to the portion of AF10 present and that there is no obvious difference between the fusions found in AML patients compared to those found in patients with lymphoid malignancies. Leukemia (2000) 14, 93-99. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results